Werewolf Therapeutics (NASDAQ:HOWL) Research Coverage Started at JMP Securities

JMP Securities started coverage on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a research note published on Wednesday, Marketbeat.com reports. The firm issued a mkt outperform rating and a $12.00 target price on the stock.

Werewolf Therapeutics Trading Down 1.3 %

NASDAQ:HOWL opened at $5.92 on Wednesday. The stock has a fifty day moving average price of $6.31 and a two-hundred day moving average price of $4.13. The company has a debt-to-equity ratio of 0.29, a quick ratio of 7.14 and a current ratio of 7.14. The stock has a market capitalization of $253.02 million, a price-to-earnings ratio of -5.69 and a beta of 0.70. Werewolf Therapeutics has a 1 year low of $1.57 and a 1 year high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.10. The firm had revenue of $1.50 million during the quarter, compared to the consensus estimate of $2.75 million. Werewolf Therapeutics had a negative return on equity of 32.25% and a negative net margin of 187.37%. As a group, sell-side analysts anticipate that Werewolf Therapeutics will post -1.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds have recently modified their holdings of the company. Financial Perspectives Inc lifted its stake in shares of Werewolf Therapeutics by 80.0% during the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock valued at $26,000 after buying an additional 3,000 shares during the period. Certuity LLC purchased a new position in shares of Werewolf Therapeutics during the 4th quarter worth $39,000. Jane Street Group LLC purchased a new position in shares of Werewolf Therapeutics during the 4th quarter worth $45,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Werewolf Therapeutics during the second quarter worth $54,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Werewolf Therapeutics in the fourth quarter valued at $56,000. 64.84% of the stock is owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.